Interim report 2026
Filed with HKEX · Stock code 6855 · · 101 pages · English
2 Corporate Information 10 Financial Highlights 12 Business Highlights 13 Management Discussion and Analysis 14 Other Information 42 Independent Review Report 78 Interim Condensed Consolidated Statement of Profit or Loss 79 Interim Condensed Consolidated Statement of Comprehensive Income or Loss 80 Interim Condensed Consolidated Statement of Financial Position 81 Interim Condensed Consolidated Sta
Ascentage Pharma Group International on 6ix
Earlier from Ascentage Pharma Group International
- Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
- CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
- Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
- Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
- Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Later from Ascentage Pharma Group International
- Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme
- Voluntary announcement - acquisition of shares by the chairman and executive director
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Ascentage Pharma Group International into a list and get an email when it puts out news.
Follow Ascentage Pharma Group International